Milgamma Mono 50 (Benfotiamine)

Benfotiamine, the active ingredient in Milgamma Mono 50, is a thiamine derivative presented as an oral supplement for oral use. It is employed to support carbohydrate metabolism and to help reduce formation of advanced glycation end‑products, particularly in individuals with metabolic stress.

GNH USA supplies Milgamma Mono 50 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory support for diverse healthcare markets. Our distribution network ensures timely delivery and adherence to quality standards.

Benfotiamine is used primarily to support metabolic pathways and conditions related to carbohydrate processing and oxidative stress. - Diabetic peripheral neuropathy: helps alleviate nerve pain and improve sensory function. - Carbohydrate metabolism support: enhances thiamine diphosphate levels to aid glucose utilization. - Advanced glycation end‑product reduction: reduces formation of AGEs associated with chronic hyperglycemia.

Benfotiamine is generally well tolerated, but some users may experience adverse reactions.

Common Side Effects: - Nausea: mild stomach upset reported in some individuals. - Headache: transient headaches may occur. - Gastrointestinal discomfort: including abdominal pain or diarrhea. - Skin rash: mild erythema or itching. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Hypersensitivity reaction: swelling, hives or difficulty breathing. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Liver enzyme elevation: marked increase in transaminases. - Anaphylaxis: rapid onset of systemic allergic response. - Hematologic abnormalities: rare cases of leukopenia.

When considering benfotiamine therapy, several precautionary measures should be observed to ensure safe use. - Assess renal function: adjust use in patients with severe kidney impairment. - Monitor blood glucose: observe for changes in glycemic control. - Avoid in known hypersensitivity: discontinue if allergic reactions develop. - Use with caution in pregnancy: safety data are limited, weigh benefits versus risks. - Use with caution while breastfeeding: insufficient information on excretion in milk. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Benfotiamine may interact with certain medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Alcohol: excessive intake may increase thiamine deficiency risk. - Anticonvulsants (e.g., phenobarbital): may accelerate thiamine metabolism, reducing effectiveness. - Loop diuretics (e.g., furosemide): increase urinary thiamine loss, potentially diminishing therapeutic benefit.

Moderate Interactions (Monitor Closely): - Metformin: monitor glucose levels as combined effect on carbohydrate metabolism may be additive. - Statins: observe for muscle-related side effects when combined with high-dose thiamine derivatives. - Vitamin B complex supplements: assess for possible excess thiamine accumulation.